Business Context and Reporting Period
This Form 6-K filing by XTL Biopharmaceuticals Ltd. covers the month of March 2026, with a report date of March 10, 2026. The filing addresses the status of a previously disclosed proposed acquisition transaction involving NeuroNOS Ltd.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
- Termination of Letter of Intent: The Letter of Intent (LOI) entered into on January 13, 2026, with Beyond Air, Inc. ("XAIR") regarding the acquisition of NeuroNOS Ltd. expired by its terms on March 9, 2026.
- No Definitive Agreement: The parties failed to enter into a definitive agreement prior to the expiration date.
- Formal Termination Notice: On March 9, 2026, XAIR notified XTL that the LOI is terminated and that both parties are released from further obligations, except for surviving confidentiality provisions.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future operations beyond the termination of the specific transaction. The primary risk disclosed is the cessation of the proposed acquisition of NeuroNOS Ltd., which removes the potential strategic or financial impact of that deal.
Key Facts for Investor Verification
- Verify the exact date of LOI expiration (March 9, 2026) and the formal notification from XAIR.
- Confirm that no definitive agreement was signed prior to the LOI expiration.
- Review the surviving confidentiality obligations to ensure no undisclosed liabilities remain.
- Check for any subsequent press releases or filings regarding alternative strategies for NeuroNOS Ltd.